Implementing the 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable chronic obstructive pulmonary disease in primary care.

Authors

Anthony D D'Urzo, Lawrence D Jackson, Jean Bourbeau, Marie-France Beauchesne, Paul Hernandez, Don D Sin, Itamar E Tamari, Mohit Bhutani, Darcy D Marciniuk, Erika Penz, Joshua Wald, Ross E G Upshur

Published in

Canadian family physician Medecin de famille canadien. Volume 72. Issue 10. Pages 610-617.

Abstract

To increase family physician (FP) awareness of the 2023 Canadian Thoracic Society (CTS) guideline recommendations on pharmacotherapy in patients with stable chronic obstructive pulmonary disease (COPD) and self-efficacy in implementing the recommendations in primary care to achieve 3 high-priority patient outcomes.
Strength and certainty of pharmacotherapy recommendations is based on meta-analysis of evidence. The strength of recommendations ranges from weak to strong and certainty ranges from low to high.
Provider awareness and self-efficacy are 2 of the most employed strategies to facilitate guideline implementation. The 2023 CTS pharmacotherapy recommendations for the management of stable COPD are based on assessment of treatable traits including symptom burden, health status, and risk of exacerbations. Key pharmacotherapy recommendations include single long-acting bronchodilator (LABD) for patients with low symptom burden and mild health status impairment; dual long-acting bronchodilator for patients with moderate-to-high symptom burden and health status impairment but low risk for exacerbations; and single-inhaler triple therapy (over dual LABD or inhaled corticosteroid and long-acting β₂-adrenergic agonist) for patients with high symptom burden and health status impairment and high risk for exacerbations to reduce mortality.
Various implementation strategies, including guideline awareness and provider self-efficacy, aim to reduce the gap between guidelines and real-world care. This synopsis aims to familiarize FPs with recommended pharmacotherapy in the context of stable COPD and gain the necessary confidence to apply the recommendations in their practices to alleviate symptoms, prevent exacerbations, and reduce mortality.

PMID:
42875068
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.